Posted Oct. 5, 2012 at 7:20 a.m.

Premium Lock Risk-averse Big Pharma just saying 'No' to small drug firm deals

Published: 2012-10-05 07:20:00
Updated: 2012-10-05 07:20:00

NU Tech roundtable NU Tech roundtable

Universities and small pharmas used to be able to reach deals where a pharmaceutical company would buy an early stage asset lock, stock and barrel. But the de-risking trend means that Big Pharma aims to structure deals in a way that pushes more risk onto the licensor. The payoff comes at the back-end of a deal -- if and when a technology reaches development and commercialization milestones....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2014 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll